1. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Issue 10 (October 2020) Authors: DiNardo, Courtney D; Maiti, Abhishek; Rausch, Caitlin R; Pemmaraju, Naveen; Naqvi, Kiran; Daver, Naval G; Kadia, Tapan M; Borthakur, Gautam; Ohanian, Maro; Alvarado, Yesid; Issa, Ghayas C; Montalban-Bravo, Guillermo; Short, Nicholas J; Yilmaz, Musa; Bose, Prithviraj; Jabbour, Elias J; Takahashi, ... Journal: Lancet Issue: Volume 7:Issue 10(2020) Page Start: e724 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Issue 9 (29th July 2022) Authors: Short, Nicholas J.; Borthakur, Gautam; Pemmaraju, Naveen; Dinardo, Courtney D.; Kadia, Tapan M.; Jabbour, Elias; Konopleva, Marina; Macaron, Walid; Ning, Jing; Ma, Junsheng; Pierce, Sherry; Alvarado, Yesid; Sasaki, Koji; Takahashi, Koichi; Estrov, Zeev; Masarova, Lucia; Issa, Ghayas C.; Montalban... Journal: Leukemia & lymphoma Issue: Volume 63:Issue 9(2022) Page Start: 2161 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A phase 1b/2 study of azacitidine with PD‐L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. Issue 20 (25th June 2021) Authors: Saxena, Kapil; Herbrich, Shelley M.; Pemmaraju, Naveen; Kadia, Tapan M.; DiNardo, Courtney D.; Borthakur, Gautam; Pierce, Sherry A.; Jabbour, Elias; Wang, Sa A.; Bueso‐Ramos, Carlos; Loghavi, Sanam; Tang, Guillin; Cheung, Cora M.; Alexander, Lynette; Kornblau, Steven; Andreeff, Michael; Garcia‐Ma... Journal: Cancer Issue: Volume 127:Issue 20(2021) Page Start: 3761 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A phase II study of omacetaxine mepesuccinate for patients with higher‐risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Issue 1 (15th November 2018) Authors: Short, Nicholas J.; Jabbour, Elias; Naqvi, Kiran; Patel, Ami; Ning, Jing; Sasaki, Koji; Nogueras‐Gonzalez, Graciela M.; Bose, Prithviraj; Kornblau, Steven M.; Takahashi, Koichi; Andreeff, Michael; Sanchez‐Petitto, Gabriela; Estrov, Zeev; Dinardo, Courtney D.; Montalban‐Bravo, Guillermo; Konopleva... Journal: American journal of hematology Issue: Volume 94:Issue 1(2019:Jan.) Page Start: 74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells. Issue 3 (15th March 2021) Authors: Ly, Stanley; Anand, Vivek; El-Dana, Fouad; Nguyen, Khoa; Cai, Yiming; Cai, Shirong; Piwnica-Worms, Helen; Tripathy, Debasish; Sahin, Aysegul A; Andreeff, Michael; Battula, Venkata Lokesh Journal: Journal for immunotherapy of cancer Issue: Volume 9:Issue 3(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Apoptosis repressor with caspase recruitment domain modulates second mitochondrial‐derived activator of caspases mimetic‐induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia. (31st July 2014) Authors: Mak, Po Y.; Mak, Duncan H.; Ruvolo, Vivian; Jacamo, Rodrigo; Kornblau, Steven M.; Kantarjian, Hagop; Andreeff, Michael; Carter, Bing Z. Journal: British journal of haematology Issue: Volume 167:Number 3(2014:Nov.) Page Start: 376 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. At the Bedside: Profiling and treating patients with CXCR4-expressing cancers. Issue 5 (22nd October 2020) Authors: Martin, Miguel; Mayer, Ingrid A; Walenkamp, Annemiek M E; Lapa, Constantin; Andreeff, Michael; Bobirca, Alexandra Journal: Journal of leukocyte biology Issue: Volume 109:Issue 5(2021) Page Start: 953 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. At the Bedside: Profiling and treating patients with CXCR4‐expressing cancers. Issue 5 (22nd October 2020) Authors: Martin, Miguel; Mayer, Ingrid A.; Walenkamp, Annemiek M.E.; Lapa, Constantin; Andreeff, Michael; Bobirca, Alexandra Journal: Journal of leukocyte biology Issue: Volume 109:Issue 5(2021) Page Start: 953 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 study. Issue 10 (October 2022) Authors: Bazinet, Alexandre; Darbaniyan, Faezeh; Jabbour, Elias; Montalban-Bravo, Guillermo; Ohanian, Maro; Chien, Kelly; Kadia, Tapan; Takahashi, Koichi; Masarova, Lucia; Short, Nicholas; Alvarado, Yesid; Yilmaz, Musa; Ravandi, Farhad; Andreeff, Michael; Kanagal-Shamanna, Rashmi; Ganan-Gomez, Irene; Coll... Journal: Lancet Issue: Volume 9:Issue 10(2022) Page Start: e756 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study. Issue 8 (3rd December 2020) Authors: Borthakur, Gautam; Ofran, Yishai; Tallman, Martin S.; Foran, James; Uy, Geoffrey L.; DiPersio, John F.; Showel, Margaret M.; Shimoni, Avichai; Nagler, Arnon; Rowe, Jacob M.; Altman, Jessica K.; Abraham, Michal; Peled, Amnon; Shaw, Stephen; Bohana‐Kashtan, Osnat; Sorani, Ella; Pereg, Yaron; Foley‐... Journal: Cancer Issue: Volume 127:Issue 8(2021) Page Start: 1246 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗